At the prestigious American Association for Cancer Research annual meeting this week, MedImmune will unveil for the first time how we are packing a one-two punch to cancer cells into one specially-engineered monoclonal antibody.
Referred to as a “bispecific”, MEDI5752 is a novel, investigational antibody that our scientists engineered to target cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on programmed cell death 1 (PD-1) expressing T-cells.1
Try to say that five times fast!
Both PD-1 and CTLA-4 are receptors on tumor T-cells that trick the immune system from going after cancer. Scientists are increasingly exploring how to tackle these immune checkpoint receptors using monoclonal antibodies. In fact, some PD-1 inhibitors and those targeting CTLA-4 have been clinically validated both individually and in combination.2
By developing individual molecules that can target two or more checkpoints on T-cells, we hope to improve upon existing single-agent checkpoint blockades in immuno-oncology and expand the patients and tumor types that respond to immunotherapy.1
In pre-clinical models, MEDI5752 binds simultaneously to both PD-1 and CTLA-4 and lands a double hit right where we want it: within the tumor, to reinvigorate the immune system response to cancer.1
Experts at MedImmune are already applying their learnings to develop additional bispecific antibodies. To do this, we merge expertise in protein engineering together with in-depth knowledge of how the immune system works.
At MedImmune we continue to expand our early science toolbox with the goal of transforming patient outcomes and ultimately curing cancer. Our teams are grounded in science. We live and breathe it from the top down and the bottom up.
After spending years in cancer research and leading teams of experts from all over the world, I have a healthy dose of optimism about the future.
1. Dovedi S, et al. MEDI5752: A novel bispecific antibody that preferentially targets CTLA-4 on PD-1 expressing T-cells [Abstract]. Presented at American Association for Cancer Research 2018 Annual Meeting, Chicago. 16 April 2018.
2. Alsaab H, et al. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. Front Pharmacol. 2017;8(561)
Date of next review: April 2020